MNK Stock Overview
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.
Mallinckrodt plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.10|
|52 Week High||US$31.00|
|52 Week Low||US$0.10|
|1 Month Change||-28.34%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.00%|
Recent News & Updates
|MNK||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how MNK performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MNK performed against the US Market.
|MNK Average Weekly Movement||15.0%|
|Pharmaceuticals Industry Average Movement||10.8%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MNK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: Insufficient data to determine MNK's volatility change over the past year.
About the Company
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products.
Mallinckrodt plc Fundamentals Summary
|MNK fundamental statistics|
Is MNK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MNK income statement (TTM)|
|Cost of Revenue||US$1.34b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-65.83|
|Net Profit Margin||-42.88%|
How did MNK perform over the long term?See historical performance and comparison